培美曲塞联合洛铂治疗晚期肺腺癌92例临床观察  

Clinical observation of pemetrexed combined with lobaplatin in the treatment of 92 cases of advanced lung adenocarcinoma

作　　者：高尔云[1] 李敏[1] 陈丽琼[1] 韩小虎[2] 

机构地区：[1]马鞍山市人民医院肿瘤科,安徽马鞍山243000 [2]马鞍山市人民医院肾内科,安徽马鞍山243000

出　　处：《现代肿瘤医学》2016年第6期899-902,共4页Journal of Modern Oncology

摘　　要：目的:观察培美曲塞联合洛铂治疗晚期肺腺癌的不良反应及临床疗效。方法:选取我院2010年1月至2013年9月收治的92例晚期肺腺癌患者,分为研究组(n=46)和对照组(n=46)。给予研究组患者培美曲塞联合洛铂治疗,对照组患者培美曲塞联合顺铂治疗。结果:研究组和对照组患者的RR 58.7%(27/46)、54.3%(25/46)和DCR 93.5%(43/46)、84.8%(39/46)、MST、PFS及1年、2年生存率之间的差异均不显著(P>0.05)。研究组不良反应中恶心、呕吐、肌酐升高明显减少,血小板减少明显增加,有统计学意义(P<0.05),对照组中恶心、呕吐、肌酐升高明显增加(P<0.05)。结论:培美曲塞联合洛铂治疗晚期肺腺癌较培美曲塞联合顺铂更能有效减少患者的不良反应,临床疗效无差异。Objective： To observe the adverse events and clinical effects of pemetrexed combined with lobaplatin in the treatment of advanced lung adenocarcinoma. Methods： All 92 patients with advanced lung cancer who were treated in our hospital from January 2010 to September 2013 were selected,they were divided into study group（ n = 46） and control group（ n = 46）. The study group were given pemetrexed combined lobaplatin treatment,while the control group were given pemetrexed plus cisplatin therapy. Results： The difference of RR 58. 7%（ 27 /46）,54. 3%（ 25 /46） and DCR 93. 5%（ 43 /46）,84. 8%（ 39 /46）,MST,PFS and 1- year 2- year survival rates between the study group and the control group were not significant（ P〈 0. 05）,the difference was not significant（ P〈 0. 05）. Adverse reactions of nausea,vomiting,elevated creatinine significantly reduced of patients in the study group with clinically acceptable,thrombocytopenia significantly increased（ P〈 0. 05）,after L- platelet therapy improved. The nausea,vomiting,elevated creatinine of the control group was significantly increased（ P〈 0. 05）. Conclusion： Pemetrexed combined lobaplatin is more effective in reducing adverse reactions of patients in the treatment of advanced lung adenocarcinoma than pemetrexed combination with cisplatin,the clinical effect is undifferentiated.

关 键 词：培美曲塞联合洛铂 晚期肺腺癌 临床效果 不良反应 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]